Peer-reviewed publications

McTigue KM, Hartelius EJ, … Larson SL, et al. Using a deliberative forum for engaging health system and health plan leaders to prioritize research topics. European Journal for Person Centered Healthcare. 2018; 6(2):228-36.

Fisher E, Hasselberg M, Conwell Y, Weiss L, Padrón NA, Tiernan E, et al. Telementoring primary care clinicians to improve geriatric mental health care. Popul Health Manage. 2017;20(5):342-347.

White papers and reports

Larson S; Padron N; Mason J; Bogaczyk T. Supervised Consumption Facilities – Review of the Evidence. December 2017.
CPHR produced a scientific review of safe injection sites as a means to help combat the opioid epidemic. The study was produced by CPHR at the request of The Office of the Health Commissioner, Philadelphia Department of Public Health. Supervised consumption facilities, also known as safe drug injection sites or comprehensive user engagement sites, are medical interventions in which essential services are provided to reduce substance use, the harms associated with substance abuse, and fatal overdoses.

In popular media

Robinson P, Onyekere C, Padron N. Know Your Community to Improve Population Health. Hospitals & Health Networks. March 2, 2017.

Chen AF, Padrón NA, Becker CM. The Social Determinants of Health. Healthcare Transformation. 2017;2(2):43-51.

Padron N. The Hard Truth Behind Philly Health Statistics. Philadelphia magazine. May 6, 2017.

Larson, S. With suicide on the rise, it should now be viewed as a population health problem. Main Line Health Well Ahead blog. July 10, 2018.

Press releases

CPHR researchers produce scientific review of safe injection facilities at request of Philadelphia city officials

LIMR names executive director of population health research

LIMR and Thomas Jefferson University collaborate to launch new Population Health Research Center

Posters

Larson S, Padron N, Bogaczyk T, Mason J. Supervised consumption facilities — a review of the evidence (PDF). Poster presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 conference. May 2018; Baltimore, MD.

Larson S, Padron N. The case for harm reduction in Philadelphia. Poster presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 conference. May 2018; Baltimore, MD.

Larson S. Factors associated with secondary non-adherence to oral hypoglycemic among patients with type 2 diabetes (PDF). American Diabetes Association Scientific Sessions. June 2018; Orlando, FL.